ArticleEuropean geriatric medicine2026
Time to remission and steroid doses in older and younger patients with polymyalgia rheumatica.
Article in European geriatric medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Age and neutrophil counts at the time of diagnosis of polymyalgia rheumatica: are they useful or confounding factors in the geriatrician's clinical practice?European geriatric medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis study aimed to compare time to remission, glucocorticoid doses on the remission achieving regimen, and clinical characteristics between older and younger patients with polymyalgia rheumatica (PMR).
methodsThis retrospective cohort study included 157 patients with PMR at a tertiary center. Patients were stratified into older (≥ 65 years, n = 78) and younger (< 65 years, n = 79) groups. Baseline demographics, comorbidities, laboratory findings, and treatment outcomes were compared. The primary outcomes were time to remission and steroid doses at the time of remission.
resultsThe mean age was 75.8 ± 8 years in the older group and 60.2 ± 3.3 years in the younger group. The majority of patients were female (82.1% in the older group and 79.7% in the younger group), with no significant difference between groups (P = 0.713). The older group showed a significantly longer time to remission (5.1 ± 1.9 months) compared with the younger group (4.0 ± 1.9 months, P < 0.001). Neutrophil counts were higher in older patients (7.0 ± 2.4 vs. 6.0 ± 2.0 × 10⁹/L, P = 0.004). Hyperlipidemia was more common in the older cohort (P = 0.023). Other comorbidities and inflammatory markers (ESR, CRP) did not differ significantly. Steroid doses required for remission were comparable across groups. Multivariable analysis identified age and neutrophil count as independent predictors of delayed remission.
conclusionsOlder PMR patients experience delayed remission despite similar glucocorticoid regimens. Elevated neutrophil counts may reflect an age-related pro-inflammatory state contributing to persistent disease activity. Tailored, age-adapted therapeutic strategies may improve outcomes in this population.
Indexed as
Identifiers
41493702What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.